NFkB-p105(Ab-893) Antibody
Product Name | NFkB-p105(Ab-893) Antibody |
Host Species | Rabbit |
Clonality | Polyclonal |
Purification | Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide. |
Applications | WB IHC |
Reactivity | Hu |
Specificity | The antibody detects endogenous level of total NFkB-p105 protein. |
Immunogen | Peptide-KLH. Peptide sequence around aa.891~895 (A-S-S-P-V) derived from Human NFkB-p105. |
Target Name | NFkB-p105 |
Alternative Name | DNA-binding factor KBF1; EBP-1; NF-kappa-B1 p84/NF-kappa-B1 p98; NFKB1; NFkB-p50 |
SDS-PAGE MW | 120kd |
Accession No | P19838; NP_001158884.1 |
Concentration | 1.0mg/ml |
Formulation | Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
Storage | Store at -20°C for long term preservation (recommended). Store at 4°C for a short term use. |
Application:
Western blotting: 1:500~1:1000
Immunohistochemistry: 1:50~1:100
Background
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively.
Hou S, et al. (2003) J Biol Chem. 278(46): 45994-45998.
Baeuerle P A, et al. (1994) Annu Rev Immunol. 12:141-179.
Baeuerle P A, et al. (1996) Cell 87:13-20.
Haskill S, et al. (1991) Cell 65:1281-1289.
| Sizes | 100ul, 50ul |
|---|
- Datasheet
Reviews
There are no reviews yet.